cGMP Standards & Compliance Framework
Table of Contents
1. Overview & Purpose
This document establishes the Current Good Manufacturing Practices (cGMP) framework for Aevum Zenth Conglomerate’s pharmaceutical, biotechnology, medical device, and advanced materials divisions. The standard ensures that all products are consistently produced and controlled according to quality specifications appropriate for their intended use.
The "c" in cGMP emphasizes that manufacturing methods, facilities, and systems must be up-to-date with current technological advancements and regulatory expectations. This standard supersedes all legacy SOPs related to manufacturing quality across Aevum Zenth subsidiaries.
2. Scope & Applicability
This standard applies to:
- All Aevum Zenth manufacturing, packaging, labeling, and testing facilities globally
- Contract manufacturers and third-party vendors processing Aevum Zenth products
- Active pharmaceutical ingredients (APIs), finished dosage forms, biologics, and combination products
- Medical device assembly, sterilization, and software-embedded hardware manufacturing
Exemptions require written approval from the Chief Quality Officer (CQO) and must be documented in the Quality Management System (QMS).
3. Quality Management System (QMS)
Aevum Zenth operates a unified, computerized QMS aligned with ISO 9001:2015 and GxP requirements. The QMS must include:
- Quality Assurance Oversight: Independent QA unit with authority to approve/reject materials, processes, and final products
- Risk Management: FMEA, HACCP, and ISO 14971 risk assessments integrated into all new product introductions (NPIs)
- Supplier Qualification: Tiered vendor audits, quality agreements, and continuous performance monitoring
- Change Control: Formal evaluation, validation, and approval of all process, equipment, and facility modifications
4. Facilities & Equipment
Manufacturing environments must maintain controlled conditions to prevent contamination, mix-ups, and cross-contamination.
| Parameter | Requirement | Documentation |
|---|---|---|
| Environmental Monitoring | ISO Class 5–8 cleanrooms per operation | EM-004 Rev 3 |
| HVAC Systems | HEPA filtration, pressure differentials ≥10–15 Pa | ENG-112 Rev 2 |
| Water Systems | Pure/ultrapure water per USP <1230> & EP 5.1 | UTIL-008 Rev 5 |
| Equipment Qualification | DQ/IQ/OQ/PK lifecycle before release | VAL-201 Rev 4 |
5. Personnel & Training
Personnel are the most critical element in GMP compliance. All manufacturing and quality staff must:
- Complete role-specific cGMP training prior to independent operation
- Undergo annual competency assessments and refresher training
- Maintain medical fitness for cleanroom entry (if applicable)
- Adhere to gowning procedures, hygiene protocols, and behavioral standards
Training records must be retained for the lifecycle of the product plus 3 years, or as required by local regulatory authorities.
6. Documentation & Data Integrity
All manufacturing and quality activities must be documented in real-time, accurately, and completely. Data integrity follows the ALCOA+ principles:
- Attributable
- Legible
- Contemporaneous
- Original
- Accurate
- + Complete, Consistent, Enduring, Available
Electronic records and signatures must comply with 21 CFR Part 11 and EU Annex 11. Audit trails must be enabled, protected from tampering, and reviewed for every critical process step.
7. Validation & Qualification
No process, method, or system may be used for commercial manufacturing without formal validation. Categories include:
- Process Validation: Stage 1 (Design) → Stage 2 (Qualification) → Stage 3 (Continued Verification)
- Cleaning Validation: Chemical & microbiological limits per health-based exposure limits (HBEL)
- Method Validation: Specificity, linearity, accuracy, precision, robustness per ICH Q2(R2)
- Computer System Validation: GAMP 5 lifecycle for all IT/OT systems impacting quality
8. Deviation Management & CAPA
Any departure from approved procedures or specifications must be documented, investigated, and resolved through a formal deviation management process.
| Classification | Impact | Response Timeline |
|---|---|---|
| Minor | No impact on product quality/patient safety | Close within 14 days |
| Major | Potential impact on quality or regulatory compliance | CAPA required within 30 days |
| Critical | Direct impact on safety, efficacy, or GMP compliance | Immediate hold, 48h root cause, 14d CAPA |
Effectiveness checks must be performed at predefined intervals to ensure CAPA implementation has resolved the root cause and prevented recurrence.
9. Regulatory References
This standard is harmonized with the following regulatory frameworks and guidelines:
- 21 CFR Part 210/211 (FDA) - Current Good Manufacturing Practice for Finished Pharmaceuticals
- EU GMP Annex 1 (2022) - Manufacture of Sterile Medicinal Products
- ICH Q7 - Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
- ISO 13485:2016 - Medical Devices - Quality Management Systems
- WHO TRS 986, Annex 2 - Good Manufacturing Practices
- PIC/S GMP Guide - WHO/ICH/EU Harmonized Standards
10. Revision History
| Version | Date | Author | Description |
|---|---|---|---|
| v4.2.0 | 2025-11-01 | Quality Strategy Office | Integrated Annex 1 2022 updates; expanded data integrity scope |
| v4.1.0 | 2025-06-15 | Dr. Elena Rostova | Added ICH Q12 alignment for post-approval changes |
| v4.0.0 | 2024-12-01 | CQO Office | Major restructuring for global multi-site deployment |
| v3.8.2 | 2024-08-20 | Compliance Engineering | Clarified computer system validation requirements |
Questions or Compliance Inquiries?
Contact the Global Quality Assurance Office: qms@aevumzenth.internal | Internal Ticket: QMS-SUPPORT-001